Peripheral T-cell lymphoma (PTCL-NOS)

The key test is a biopsy. When it is possible, doctors prefer to remove a whole lymph node (excisional biopsy) rather than take a thin needle core. A whole node gives the lab enough tissue for all the tests it needs.

Lab doctors (pathologists) look for T-cell markers on the cancer cells, such as CD3 and CD4. They also check for CD30, because that result can shape treatment. Other tests look for a single family of T cells (a clonal T-cell receptor rearrangement) and at the cells' chromosomes. Telling T-cell lymphomas apart is hard, and sometimes more than one biopsy is needed. The NCI advises that an expert lymphoma pathologist (hematopathologist) review the biopsy. In one large international study, about 1 in 10 cases first sent in as a T-cell lymphoma turned out to be something else.

Staging shows where the lymphoma is. It usually includes a PET-CT scan, blood tests such as LDH, and tests for HIV, hepatitis B and C, and HTLV-1. A bone marrow biopsy is usually done when the lymphoma is at an advanced stage. A heart scan is done before chemotherapy that uses an anthracycline drug, such as doxorubicin.

Initial treatment often uses an anthracycline-containing chemotherapy combination. For selected CD30-positive disease, brentuximab vedotin-containing treatment may be considered. Clinical trials are valuable because the group is uncommon and treatment results vary.

After a response, some fit patients receive high-dose chemotherapy followed by autologous stem cell rescue. This uses their own collected cells. First-remission consolidation is an individualized option; evidence from pooled T-cell lymphoma studies does not prove the same benefit for every PTCL-NOS patient.

For relapsed or refractory disease, salvage treatment may include different chemotherapy or targeted medicines. Allogeneic transplantation can offer durable control for selected patients, but its risks, disease response and available alternatives must be weighed together.

PTCL-NOS is an aggressive lymphoma, and it often comes back after first treatment. Outlook differs a great deal from person to person. Things that matter include age, general fitness, stage, LDH level and how many places outside the lymph nodes are involved. Scoring tools such as the International Prognostic Index (IPI) and the newer T-cell score use factors like these to sort people into lower and higher risk groups.

How the lymphoma responds to first treatment is one of the strongest signs. In a large study, people who were alive and free of lymphoma two years after diagnosis did much better from then on. People aged 60 or younger in that group did best. People whose lymphoma grew or came back within two years faced a much harder road.

When first treatment works, some teams offer a transplant with the person's own stem cells to try to keep the lymphoma away. If it comes back, European transplant guidelines call a donor transplant the only treatment that can cure it, for people well enough to have one. Because PTCL-NOS is uncommon, clinical trials are an important part of care.